Mind Club

Data as of 11.07.2026 · Primary sources linked · NOT INVESTMENT ADVICE

Disease Pipeline Tools Obesity

Obesity

Programs, trials, and reported weight change for obesity and overweight.

Data as of 11.07.2026

All studies

Setmelanotide

DAYBREAK: A Study of Setmelanotide in Participants With Specific Gene Variants in the Melanocortin-4 Receptor (MC4R) Pathway

Rhythm · Phase 2 · Completed · Enrollment 164

NCT04963231

Participants reaching a weight loss threshold

Participants reaching threshold, %

Source: Cited trial source. The denominator is the source figure, when it states one.

No selected arm reports a responder percent.

Show as table
Arm≥5%≥10%≥15%≥20%
Stage 1: Setmelanotide (Open-Label)n/rn/rn/rn/r
Stage 2: Setmelanotide (Double-Blind)n/rn/rn/rn/r
Stage 2: Placebo (Double-Blind)n/rn/rn/rn/r

Not shown

  • Stage 1: Setmelanotide (Open-Label): endpoint not reported
  • Stage 2: Setmelanotide (Double-Blind): endpoint not reported
  • Stage 2: Placebo (Double-Blind): endpoint not reported